argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
774.75
-9.00 (-1.15%)
At close: Apr 28, 2026, 4:00 PM EDT
775.03
+0.28 (0.04%)
After-hours: Apr 28, 2026, 4:00 PM EDT
argenx SE Employees
argenx SE had 1,863 employees as of December 31, 2025. The number of employees increased by 264 or 16.51% compared to the previous year.
Employees
1,863
Change (1Y)
264
Growth (1Y)
16.51%
Revenue / Employee
$2,274,004
Profits / Employee
$693,524
Market Cap
48.47B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1,863 | 264 | 16.51% |
| Dec 31, 2024 | 1,599 | 451 | 39.29% |
| Dec 31, 2023 | 1,148 | 305 | 36.18% |
| Dec 31, 2022 | 843 | 193 | 29.69% |
| Dec 31, 2021 | 650 | 314 | 93.45% |
| Dec 31, 2020 | 336 | 148 | 78.72% |
| Dec 31, 2019 | 188 | 83 | 79.05% |
| Dec 31, 2018 | 105 | 32 | 43.84% |
| Dec 31, 2017 | 73 | 15 | 25.86% |
| Dec 31, 2016 | 58 | 17 | 41.46% |
| Dec 31, 2015 | 41 | 9 | 28.13% |
| Dec 31, 2014 | 32 | 10 | 45.45% |
| Dec 31, 2013 | 22 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Vertex Pharmaceuticals | 6,400 |
| Moderna | 4,700 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
ARGX News
- 7 days ago - Noteworthy ETF Outflows: IBB, REGN, ARGX, INSM - Nasdaq
- 9 days ago - argenx (ARGX) Reveals New Vyvgart Data at 2026 AAN Annual Meeting - GuruFocus
- 10 days ago - argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP - GlobeNewsWire
- 11 days ago - Wedbush Reaffirms ARGX, NUVB, FENC At Outperform; Lifts PT For Kiniksa; Keeps NVCR At Neutral - Nasdaq
- 26 days ago - Oppenheimer Lowers Price Target for ARGX, Reiterates Outperform Rating | ARGX Stock News - GuruFocus
- 27 days ago - Goldman Sachs Highlights Argenx (ARGX) as Prime Growth Opportunity - GuruFocus
- 5 weeks ago - eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency - Business Wire
- 7 weeks ago - argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - GlobeNewsWire